UK – Ipsen’s cabozantinib receives NICE approval for advanced hepatocellular carcinoma

Ipsen’s cabozantinib has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for patients with previously treated advanced hepatocellular carcinoma (HCC).

Specifically, the recommendation is for adult patients who have had sorafenib – the standard initial treatment for advanced disease – only if they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group performance status of zero or one.

NICE’s decision is based on positive results from the global placebo-controlled CELESTIAL phase 3 pivotal trial in patients in the second or third line after treatment with sorafenib…